Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR2 | P41587 | 6/20 | 0.54 |
| ▸ | BACE1 | P56817 | 5/20 | 0.54 |
| ▸ | VIPR1 | P32241 | 4/20 | 0.54 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.54 |
| ▸ | F2 | P00734 | 2/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30362779 | 0.94 | VIPR2 (0.53) | VIPR2BACE1VIPR1BACE2F2 | |
| SCHEMBL30543189 | 0.94 | VIPR2 (0.53) | VIPR2BACE1VIPR1BACE2F2 | |
| SCHEMBL29425538 | 0.92 | VIPR2 (0.51) | VIPR2BACE1VIPR1BACE2F2 | |
| SCHEMBL29462368 | 0.90 | VIPR2 (0.50) | VIPR2BACE1VIPR1BACE2F2 | |
| SCHEMBL30741250 | 0.90 | VIPR2 (0.56) | VIPR2BACE1VIPR1BACE2F2 | |
| SCHEMBL29903357 | 0.90 | VIPR1 (0.54) | VIPR2BACE1VIPR1BACE2 | |
| SCHEMBL29686064 | 0.89 | F2 (0.59) | VIPR2BACE1VIPR1F2KISS1R | |
| SCHEMBL29686194 | 0.89 | F2 (0.59) | VIPR2BACE1VIPR1F2KISS1R | |
| SCHEMBL31182852 | 0.88 | TFPI (0.59) | VIPR2VIPR1 | |
| SCHEMBL31472579 | 0.88 | BACE1 (0.62) | VIPR2BACE1VIPR1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4436990-A1 | CELL DELIVERY COMPOSITIONS AND METHODS OF USE THEREOF | The Regents of the University of California (US) | 2024-10-02 | — | — | EP | claimed |
| WO-2023097222-A1 | CELL DELIVERY COMPOSITIONS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-01 | — | — | WO | claimed |
| US-12540172-B2 | Therapeutic nanoconjugates comprising Stefin A and uses thereof | UNIVERSITAT AUTONOMA DE BARCELONA (UAB) (ES) | 2026-02-03 | — | — | US | disclosed |
| US-20250243250-A1 | THERAPEUTIC NANOCONJUGATES AND USES THEREOF | UNIV AUTÒNOMA DE BARCELONA UAB (ES) | 2025-07-31 | — | — | US | disclosed |
| US-12202866-B2 | Therapeutic nanoconjugates and uses thereof | UNIVERSITAT AUTONOMA DE BARCELONA (UAB) (ES) | 2025-01-21 | — | — | US | disclosed |
| EP-4436990-A1 | CELL DELIVERY COMPOSITIONS AND METHODS OF USE THEREOF | The Regents of the University of California (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-116836230-A | Cyclic heptapeptide FZ1 with activity of promoting diabetic skin ulcer repair and application thereof | 昆明医科大学 | 2023-10-03 | — | — | CN | disclosed |
| WO-2023097222-A1 | CELL DELIVERY COMPOSITIONS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20230068834-A1 | SCAFFOLD PROTEINS AND THERAPEUTIC NANOCONJUGATES BASED ON NIDOGEN | FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU (ES) | 2023-03-02 | — | — | US | disclosed |
| EP-4081538-A1 | SCAFFOLD PROTEINS AND THERAPEUTIC NANOCONJUGATES BASED ON NIDOGEN | Universitat Autònoma de Barcelona (ES) | 2022-11-02 | — | — | EP | disclosed |
| CN-111235156-B | Immune regulatory peptide derived from rana huashanensis and application of gene thereof in skin photodamage protection | 温州医科大学 | 2022-08-09 | — | — | CN | disclosed |
| US-11286299-B2 | Peptides selective for Bcl-2 family proteins | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-03-29 | — | — | US | disclosed |
| US-20220072084-A1 | THERAPEUTIC NANOCONJUGATES AND USES THEREOF | UNIVERSITAT AUTONOMA DE BARCELONA (UAB) (ES) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540172-B2 | Therapeutic nanoconjugates comprising Stefin A and uses thereof | MYOF, MSTN, NGLY1 | VIPR2 1771/4885BACE1 2574/4885VIPR1 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.